EAI045 is primarily researched for its potential in cancer treatment, specifically targeting mutant forms of the EGFR (Epidermal Growth Factor Receptor) protein. It is known to inhibit EGFR mutations that are resistant to first and second-generation EGFR inhibitors, making it a promising candidate for treating non-small cell lung cancer (NSCLC) patients who have developed resistance to earlier therapies. EAI045 works by binding to allosteric sites on the EGFR protein, which helps in blocking the signaling pathways that promote tumor growth. Its application is still largely in the experimental and preclinical stages, with ongoing studies aimed at optimizing its efficacy and safety profile for potential clinical use.